Join        Login             Stock Quote

biOasis' BT2111-Herceptin(R) Program Achieves Significant Positive Results From Antibody Dependent Cell-Mediated Cytotoxicity Assay

Tuesday, March 13, 2012 9:00 AM


VANCOUVER, BRITISH COLUMBIA -- (Marketwire) -- 03/13/12 -- biOasis Technologies Inc. (TSX VENTURE:BTI) today announces positive test results from its Transcend therapeutic BT2111 development program directed towards the delivery of the therapeutic monoclonal antibody Herceptin® to the brain. An ADCC (antibody dependent cell-mediated cytotoxicity) assay showed that BT2111 conjugates retained Fc receptor binding activity and mediated human immune cell killing of HER2+ breast cancer cell line. The ADCC assay is used to measure the human immune system activity directed against Herceptin® bound to HER2+ cancer cells and is considered a good predictor of anti cancer activity. This positive ADCC activity complements previous results, obtained by the British Columbia Cancer Agency, which showed that BT2111 is able to bind to HER2+ cancer cells and kill them.

"The BT2111-Herceptin® program is advancing exceptionally well," said Rob Hutchison, CEO. "Herceptin® is known to have two types of activity against HER2+ breast cancer cells. We showed through the work performed at the British Columbia Cancer Agency that BT2111 was very effective in killing HER2+ cancer cells directly through HER2+ binding. Now, the ADCC assay confirms that the BT2111 conjugate functions to induce cell mediated cytotoxic activity against HER2+ cancer cells by facilitating the binding of human natural killer cells to HER2+ breast cancer cells. The ADCC assay results provides us with further confidence to advance the BT2111 program."

(i)Herceptin® is the registered trademark of Genentech, Inc.


biOasis is developing a proprietary vector for the transport of therapeutic and imaging agents across the blood-brain barrier - Transcend. Current initiatives within the Transcend program include production of materials for preclinical studies and conjugation of Transcend to a range of small molecule and large molecule biologic therapeutics, including monoclonal antibodies.


Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.